News
If you are anywhere near Ann Arbor, Michigan, you would be well advised to check out the University of Michigan’s Patient-2-Patient (P2P) Education Project. This… 
The IBD Social Circle is hosting a twitter chat on Monday, October 16th at 8pm ET. The topic for this chat is Intimacy and Dating with… 
Methotrexate is an immunosuppressant medication sometimes used in the treatment of Inflammatory Bowel Disease. On April 23, 2015, Mylan N.V. pharmaceuticals, voluntarily recalled lot #7801082… 
Registration is now open for the 2015 season of CCFA’s Camp Oasis! Camp Oasis is a summer camp program for children with Crohn’s disease… The delta of 33% for clinical remission by CDAI is pretty impressive, especially with a lot of bio-experienced patients. Larger than IFX in the bionaive era in ACCENT. https://twitter.com/mchiorean4/status/1524768083285405697
Upadacitinib (selective JAK1-inhibitor) achieved all clinical & endoscopic endpoints for maintenance in #CrohnsDisease in the phase 3 program. Number needed to treat of 3 for clinical and 4 for endoscopic endpoints. Great news for our #IBD patients https://news.abbvie.com/news/press-releases/upadacitinib-rinvoq-achieved-clinical-remission-and-endoscopic-response-at-one-year-in-phase-3-maintenance-study-in-patients-with-crohns-disease.htm?view_id=2421
